Switch theme
Sign up to access all valuation multiples
Ourofino SA is engaged in research, development, production and sales of medicines, vaccines and other veterinary products. The company's reportable segments are Production animals, Companion animals, and International operations. It generates maximum revenue from the Production animals segment. The product portfolio includes Anticoccidials, Antimastitics, Biological, Ectoparasiticides, Endectocides, and others.
2014
1.1K+
LTM Revenue n/a
LTM EBITDA n/a
$229M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Ourofino has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Ourofino achieved revenue of $179M and an EBITDA of $42.9M.
Ourofino expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Ourofino valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $164M | $179M | XXX | XXX | XXX |
| Gross Profit | $92.1M | $75.3M | XXX | XXX | XXX |
| Gross Margin | 56% | 42% | XXX | XXX | XXX |
| EBITDA | $22.3M | $42.9M | XXX | XXX | XXX |
| EBITDA Margin | 14% | 24% | XXX | XXX | XXX |
| Net Profit | $22.8M | -$8.7M | XXX | XXX | XXX |
| Net Margin | 14% | -5% | XXX | XXX | XXX |
| Net Debt | $43.1M | $22.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Ourofino's stock price is BRL 22 (or $4).
Ourofino has current market cap of BRL 1.2B (or $204M), and EV of BRL 1.3B (or $229M).
See Ourofino trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $229M | $204M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Ourofino has market cap of $204M and EV of $229M.
Ourofino's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Ourofino's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Ourofino and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $229M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | XXX | XXX |
| EV/EBITDA | 5.3x | XXX | XXX | XXX |
| P/E | 8.7x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 44.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpOurofino's NTM/LTM revenue growth is n/a
Ourofino's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Ourofino's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Ourofino's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Ourofino and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 92% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 32% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Ourofino acquired XXX companies to date.
Last acquisition by Ourofino was XXXXXXXX, XXXXX XXXXX XXXXXX . Ourofino acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Ourofino founded? | Ourofino was founded in 2014. |
| Where is Ourofino headquartered? | Ourofino is headquartered in Brazil. |
| How many employees does Ourofino have? | As of today, Ourofino has 1.1K+ employees. |
| Is Ourofino publicy listed? | Yes, Ourofino is a public company listed on BVMF. |
| What is the stock symbol of Ourofino? | Ourofino trades under OFSA3 ticker. |
| When did Ourofino go public? | Ourofino went public in 2014. |
| Who are competitors of Ourofino? | Similar companies to Ourofino include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Ourofino? | Ourofino's current market cap is $204M |
| What is the current revenue growth of Ourofino? | Ourofino revenue growth between 2023 and 2024 was 9%. |
| Is Ourofino profitable? | Yes, Ourofino is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
